F90
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ADHD according to the DSM-5 criteria as measured by the IDA-R interview, age between 16;00 to 45;11 years;
Exclusion criteria
Exclusion criteria: IQ = 80, acute substance dependence (alcohol and illegal drugs), antisocial personality disorder, any psychotic disorder, any severe affective or bipolar disorder, epilepsy, any significant heart disease, pregnancy, insufficient command over the German language
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the ADHD symptoms by blinded expert rater via structured interview IDA-R at T0//1, T2, T3 and T4 T0/T1: at start of study T2: after completion of step 1 (after 3 months) T3: after completion of step 2 (after 6 months) T4: after 3 months follow-up (after 9 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| - WFIRS-S, which is a self-rating scale for the assessment of functional problems in 7 domains of daily life; at T1; T2, T3, T4. - Wender-Reimherr Interview. This is the German version of a structured interview to assess ADHD symptoms; at T1, T2, T3 and T4 - The AAQOL is a 29-item disease-specific quality-of-life measure; at T1, T2, T3 and T4 - SCL-90-R : a 90-item self-report symptom inventory to measure psychological symptoms and psychological distress: at T1, T2, T3 and T4 - PSQI : self-rated questionnaire which assesses sleep quality and disturbance over a 1-month time interval; at T1, T2, T3 and T4 - Anger-management will be assessed by the State-Trait Anger Expression Inventory – 2 (STAXI-2); at T1, T2, T3 and T4 - For the assessment of the psychopathology of comorbid conditions the Symptom-Checklist--90-symptom will be used; at T0, T1, T2, T3 and T4 - Aspects of quality of life will be assessed by the Adult ADHD Quality-of-Life Scale Questionnaire (AAQOL-29) at T1, T2, T3 and T4. - M.I.N.I. 6.0: The M.I.N.I is a short, structured diagnostic interview and is a structured psychiatric interview of choice for psychiatric evaluation and outcome tracking in clinical psychopharmacology trials and epidemiological studies; at T0. | — |
Countries
Germany
Contacts
Universität des Saarlandes - Institut für Gerichtliche Psychologie und Psychiatrie